LOUISVILLE, Ky.--(BUSINESS WIRE)--Apr. 30, 2009--
PharMerica Corporation (NYSE: PMC):
-
Net Income for the First Quarter 2009 was $8.2 Million, or $0.27
Diluted Earnings Per Share
-
Integration, Merger and Acquisition Related Costs and Other
Charges were $2.0 Million, or $0.04 Diluted Effect on Earnings Per
Share
-
Adjusted EBITDA was $25.2 Million for the First Quarter 2009
-
Revenues for the First Quarter 2009 were $468.2 Million
-
Cash Flow Provided by Operating Activities for First Quarter
2009 was $13.9 Million
PharMerica Corporation (NYSE: PMC), a national provider of institutional
pharmacy and hospital pharmacy management services, today reported the
results of its first quarter ended March 31, 2009. The Company also
updated its earnings guidance for 2009.
Management Commentary
In commenting on the Company’s results for the quarter, Gregory S.
Weishar, PharMerica Corporation’s Chief Executive Officer, said, “We are
pleased with first quarter 2009 results. We are realizing the benefits
from our key initiatives over the past year. In addition, we are seeing
favorable margin expansion from increased generic use. By the end of
this year, we estimate savings for our customers of over $250 million on
an annual basis. However, generic dispensing continues to pressure top
line revenue growth. We are also pleased to report continued improvement
in cash flow as we improve billing and collection processes.”
First Quarter Ended March 31, 2009
Highlights
-
Net income was $8.2 million; a 148% increase over the first quarter of
2008.
-
Diluted earnings per share were $0.27 compared to $0.11 for the
first quarter of 2008.
-
Integration, merger and acquisition related costs and other
charges were $2.0 million ($1.2 million, net of tax, or $0.04
diluted effect on earnings per share).
-
Diluted earnings per share excluding the integration, merger and
acquisition related costs and other charges were $0.31; a 63%
increase over the first quarter of 2008.
-
Adjusted EBITDA was $25.2 million.
-
This represents a 19.4% increase over the first quarter of 2008.
-
Margins improved 110 basis points to 5.4%.
-
Synergies continue to materialize from 2008 pharmacy
consolidations.
-
Revenues were $468.2 million; a decrease of $26.9 million from the
first quarter of 2008.
-
Prescriptions dispensed were 9,919,000; a 3% decrease from the
first quarter of 2008.
-
Calendar days in quarter impacted prescriptions dispensed
approximately 110,000.
-
Revenues impacted by approximately 450 basis points increase in
the generic dispensing rate.
-
Gross margins were $72.5 million on lower revenues.
-
Gross margins improved 90 basis points to 15.5%.
-
Gross margins improved as a result of increased generic dispensing
and merger and integration synergies.
-
Cash flows of $13.9 million showed continued strength.
-
Cash flows from operations improved 24.1% over the first quarter
of 2008.
-
Cash flows from operations exceeded net income by 70%.
-
Leverage ratio improved from 2.6 X EBITDA in the first quarter of 2008
to 2.0 X EBITDA in the first quarter of 2009.
Fiscal 2009 Earnings Guidance
The revised fiscal 2009 earnings guidance is as follows:
|
(in millions, except per share data)
|
|
Ranges
|
|
Revenues
|
|
$1,870.0 - $1,905.0
|
|
Adjusted earnings before interest, taxes, depreciation,
amortization, integration, merger and acquisition related costs
and other charges
|
|
$100.0 - $102.5
|
|
Depreciation and amortization expense
|
|
$28.8 - $28.2
|
|
Interest expense, net
|
|
$13.0 - $12.5
|
|
Tax rate
|
|
41.5% - 41.0%
|
|
Net income
|
|
$34.0 - $36.5
|
|
Diluted earnings per share
|
|
$1.11 - $1.18
|
|
Common and common equivalent shares outstanding
|
|
30.8
|
|
Capital expenditures
|
|
$28.4
|
The lower revenue guidance is primarily the result of a higher generic
dispensing rate, which reduced revenues and at the same time improved
margins. The earnings guidance does not reflect any significant changes
in reimbursement or material acquisitions.
Conference Call
Management will hold a conference call to review the financial results
for the first quarter ended March 31, 2009, on May 1, 2009, at 10:00
a.m. ET. To access the live webcast, visit the Investor Relations
section of the Company’s website at www.pharmerica.com
or go to www.earnings.com.
To access a telephonic replay of the call, which will be available one
hour after the conclusion of the call through May 15, 2009, please dial
1-888-286-8010 (617-801-6888 if calling from outside the U.S.) and use
passcode 35003118.
About PharMerica
PharMerica Corporation is a leading institutional pharmacy services
company servicing healthcare facilities in the United States. As of
March 31, 2009, PharMerica operated approximately 100 institutional
pharmacies in 40 states. PharMerica’s customers are institutional
healthcare providers, such as nursing centers, assisted living
facilities, hospitals and other long-term care providers. The Company
also provides pharmacy management services to long-term care hospitals.
This press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, which
reflect the Company’s current estimates, expectations and projections
about its future results, performance, prospects and opportunities. Forward-looking
statements include, among other things, the Company’s continued focus on
its initiatives of growing our client base, improving client retention
and streamlining our operations and billing processes, the information
concerning the Company’s “guidance” and possible future results of
operations, the Company’s ability to purchase acquisition targets, and
the strength of the Company’s financial performance during 2009. Forward-looking
statements include statements that are not historical facts and can be
identified by forward-looking words such as “anticipate,” “believe,”
“could,” “estimate,” “expect,” “intend,” “plan,” “may,” “should,”
“will,” “would,” “project” and similar expressions. These
forward-looking statements are based upon information currently
available to us and are subject to a number of risks, uncertainties and
other factors that could cause the Company’s actual results,
performance, prospects or opportunities to differ materially from those
expressed in, or implied by, these forward-looking statements. Important
factors that could cause the Company’s actual results to differ
materially from the results referred to in the forward-looking
statements we make in this press release are included in the Risk
Factors section set forth in the Company’s Annual Report on Form 10-K
filed with the SEC and in other reports, including current reports on
Form 10-Q, filed with the SEC by the Company.
You are cautioned not to place undue reliance on any forward-looking
statements, all of which speak only as of the date of this press release.
Except as required by law, we undertake no obligation to publicly
update or release any revisions to these forward-looking statements to
reflect any events or circumstances after the date of this press release
or to reflect the occurrence of unanticipated events. All
subsequent written and oral forward-looking statements attributable to
us or any person acting on the Company’s behalf are expressly qualified
in their entirety by the cautionary statements contained or referred to
in this press release and in the Risk Factors section set forth in the
Company’s Annual Report on Form 10-K filed with the SEC and in other
reports filed with the SEC by the Company.
|
PHARMERICA CORPORATION
|
|
UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENTS
|
|
(In millions, except share and per share amounts)
|
|
|
|
|
|
Three Months Ended March 31,
|
|
|
|
2008
|
|
2009
|
|
|
|
Amount
|
|
% of
Revenues
|
|
Amount
|
|
% of
Revenues
|
|
Revenues
|
|
$
|
495.1
|
|
100.0
|
%
|
|
$
|
468.2
|
|
100.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Cost of goods sold
|
|
|
422.6
|
|
85.4
|
|
|
|
395.7
|
|
84.5
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
|
72.5
|
|
14.6
|
|
|
|
72.5
|
|
15.5
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
57.3
|
|
11.7
|
|
|
|
52.0
|
|
11.1
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense
|
|
|
1.6
|
|
0.3
|
|
|
|
1.8
|
|
0.4
|
|
|
|
|
|
|
|
|
|
|
|
|
Integration, merger and acquisition related costs and other charges
|
|
|
4.1
|
|
0.8
|
|
|
|
2.0
|
|
0.4
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
9.5
|
|
1.8
|
|
|
|
16.7
|
|
3.6
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net
|
|
|
3.7
|
|
0.7
|
|
|
|
3.2
|
|
0.7
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
5.8
|
|
1.1
|
|
|
|
13.5
|
|
2.9
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
|
2.5
|
|
0.5
|
|
|
|
5.3
|
|
1.1
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
3.3
|
|
0.6
|
%
|
|
$
|
8.2
|
|
1.8
|
%
|
|
|
|
Three Months Ended
March 31,
|
|
|
|
2008
|
|
2009
|
|
Earnings per common share:
|
|
|
|
|
|
Basic
|
|
$
|
0.11
|
|
$
|
0.27
|
|
Diluted
|
|
$
|
0.11
|
|
$
|
0.27
|
|
|
|
|
|
|
|
Shares used in computing earnings per common share:
|
|
|
|
|
|
Basic
|
|
|
30,064,929
|
|
|
30,211,699
|
|
Diluted
|
|
|
30,086,020
|
|
|
30,311,930
|
|
PHARMERICA CORPORATION
|
|
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
|
|
(In millions, except share and per share amounts)
|
|
|
|
|
|
Dec. 31,
2008
|
|
March 31,
2009
|
|
|
|
|
|
|
|
ASSETS
|
|
Current assets:
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
41.3
|
|
|
$
|
52.1
|
|
|
Accounts receivable, net
|
|
|
219.3
|
|
|
|
218.7
|
|
|
Inventory
|
|
|
73.4
|
|
|
|
72.0
|
|
|
Deferred tax assets
|
|
|
24.9
|
|
|
|
40.7
|
|
|
Prepaids and other assets
|
|
|
16.7
|
|
|
|
13.8
|
|
|
|
|
|
375.6
|
|
|
|
397.3
|
|
|
|
|
|
|
|
|
Equipment and leasehold improvements
|
|
|
97.1
|
|
|
|
101.7
|
|
|
Accumulated depreciation
|
|
|
(43.1
|
)
|
|
|
(47.4
|
)
|
|
|
|
|
54.0
|
|
|
|
54.3
|
|
|
|
|
|
|
|
|
Deferred tax assets, net
|
|
|
59.4
|
|
|
|
37.7
|
|
|
Goodwill
|
|
|
113.7
|
|
|
|
113.7
|
|
|
Intangible assets, net
|
|
|
73.4
|
|
|
|
71.6
|
|
|
Other
|
|
|
3.1
|
|
|
|
3.0
|
|
|
|
|
$
|
679.2
|
|
|
$
|
677.6
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
Current liabilities:
|
|
|
|
|
|
Accounts payable
|
|
$
|
54.4
|
|
|
$
|
46.6
|
|
|
Salaries, wages and other compensation
|
|
|
36.3
|
|
|
|
31.4
|
|
|
Other accrued liabilities
|
|
|
12.6
|
|
|
|
11.9
|
|
|
|
|
|
103.3
|
|
|
|
89.9
|
|
|
|
|
|
|
|
|
Long term debt
|
|
|
240.0
|
|
|
|
240.0
|
|
|
Other long term liabilities
|
|
|
16.1
|
|
|
|
17.7
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ equity:
|
|
|
|
|
|
Preferred stock, $0.01 par value per share; 1,000,000 shares
authorized and no shares issued at December 31, 2008 and March 31,
2009
|
|
|
–
|
|
|
|
–
|
|
|
Common stock, $0.01 par value; 175,000,000 shares authorized;
30,477,558 shares and 30,484,522 shares issued and outstanding as of
December 31, 2008 and March 31, 2009, respectively
|
|
|
0.3
|
|
|
|
0.3
|
|
|
Capital in excess of par value
|
|
|
338.7
|
|
|
|
339.5
|
|
|
Accumulated other comprehensive loss
|
|
|
(2.8
|
)
|
|
|
(1.6
|
)
|
|
Retained deficit
|
|
|
(16.4
|
)
|
|
|
(8.2
|
)
|
|
|
|
|
319.8
|
|
|
|
330.0
|
|
|
|
|
$
|
679.2
|
|
|
$
|
677.6
|
|
|
PHARMERICA CORPORATION
|
|
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
(In millions)
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
|
|
2008
|
|
2009
|
|
Cash flows provided by (used in) operating activities:
|
|
|
|
|
|
Net income
|
|
$
|
3.3
|
|
|
$
|
8.2
|
|
|
Adjustments to reconcile net income to net cash provided by (used
in) operating activities:
|
|
|
|
|
|
Depreciation
|
|
|
5.9
|
|
|
|
4.7
|
|
|
Amortization
|
|
|
1.6
|
|
|
|
1.8
|
|
|
Integration, merger and acquisition related costs and other charges
|
|
|
0.5
|
|
|
|
0.2
|
|
|
Stock-based compensation
|
|
|
1.0
|
|
|
|
0.6
|
|
|
Amortization of deferred financing fees
|
|
|
0.1
|
|
|
|
0.1
|
|
|
Deferred income taxes
|
|
|
2.5
|
|
|
|
4.8
|
|
|
Loss on disposition of equipment
|
|
|
–
|
|
|
|
0.1
|
|
|
Other
|
|
|
(0.3
|
)
|
|
|
(0.1
|
)
|
|
Change in operating assets and liabilities:
|
|
|
|
|
|
Accounts receivable, net
|
|
|
(4.4
|
)
|
|
|
0.6
|
|
|
Inventory and other assets
|
|
|
(2.4
|
)
|
|
|
1.4
|
|
|
Prepaids and other assets
|
|
|
4.9
|
|
|
|
3.1
|
|
|
Accounts payable
|
|
|
1.2
|
|
|
|
(8.0
|
)
|
|
Salaries, wages and other compensation
|
|
|
(2.4
|
)
|
|
|
(5.0
|
)
|
|
Other accrued liabilities
|
|
|
(0.3
|
)
|
|
|
1.4
|
|
|
Net cash provided by operating activities
|
|
|
11.2
|
|
|
|
13.9
|
|
|
Cash flows provided by (used in) investing activities:
|
|
|
|
|
|
Purchase of equipment and leasehold improvements
|
|
|
(8.2
|
)
|
|
|
(3.2
|
)
|
|
Cash proceeds from sale of assets
|
|
|
0.1
|
|
|
|
–
|
|
|
Net cash used in investing activities
|
|
|
(8.1
|
)
|
|
|
(3.2
|
)
|
|
|
|
|
|
|
|
Cash flows provided by (used in) financing activities:
|
|
|
|
|
|
Repayments of long-term debt and capital lease obligations
|
|
|
(10.0
|
)
|
|
|
(0.1
|
)
|
|
Issuance of common stock
|
|
|
–
|
|
|
|
0.1
|
|
|
Cash contributions received from minority shareholders
|
|
|
0.1
|
|
|
|
–
|
|
|
Tax benefit from stock-based compensation
|
|
|
–
|
|
|
|
0.1
|
|
|
Net cash provided by (used in) financing activities
|
|
|
(9.9
|
)
|
|
|
0.1
|
|
|
|
|
|
|
|
|
Change in cash and cash equivalents
|
|
|
(6.8
|
)
|
|
|
10.8
|
|
|
Cash and cash equivalents at beginning of period
|
|
|
32.0
|
|
|
|
41.3
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
25.2
|
|
|
$
|
52.1
|
|
|
|
|
|
|
|
|
Supplemental information:
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
4.0
|
|
|
$
|
3.3
|
|
|
Cash paid for taxes
|
|
$
|
0.3
|
|
|
$
|
0.3
|
|
|
|
|
|
|
|
|
Supplemental schedule of non-cash activities:
|
|
|
|
|
|
Fair value of assets acquired
|
|
$
|
(1.4
|
)
|
|
$
|
–
|
|
|
Fair value of liabilities assumed or incurred
|
|
$
|
(1.4
|
)
|
|
$
|
–
|
|
|
Capital lease obligations
|
|
$
|
–
|
|
|
$
|
1.8
|
|
|
PHARMERICA CORPORATION
|
|
SUPPLEMENTAL INFORMATION
|
|
|
|
INTEGRATION, MERGER AND ACQUISITION RELATED COSTS AND OTHER
CHARGES
|
|
(In millions, except per share amounts)
|
|
|
|
The following is a summary of integration, merger and acquisition
related costs and other charges incurred by PharMerica in the
first quarter of 2008 and 2009 (unaudited).
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
|
2008
|
|
2009
|
|
Integration costs and other charges:
|
|
|
|
|
|
Professional and advisory fees
|
|
$
|
0.2
|
|
|
$
|
–
|
|
|
General and administrative
|
|
|
1.1
|
|
|
|
0.2
|
|
|
Employee costs
|
|
|
1.6
|
|
|
|
0.8
|
|
|
Severance costs
|
|
|
0.3
|
|
|
|
0.4
|
|
|
Facility costs
|
|
|
0.9
|
|
|
|
0.6
|
|
|
|
|
|
4.1
|
|
|
|
2.0
|
|
|
Acquisition costs:
|
|
|
|
|
|
Professional and advisory fees
|
|
|
–
|
|
|
|
–
|
|
|
Other costs
|
|
|
–
|
|
|
|
–
|
|
|
|
|
|
–
|
|
|
|
–
|
|
|
Total integration, merger and acquisition related costs and other
charges
|
|
$
|
4.1
|
|
|
$
|
2.0
|
|
|
Negative effect on diluted earnings per share
|
|
$
|
(0.08
|
)
|
|
$
|
(0.04
|
)
|
|
PHARMERICA CORPORATION
|
|
SUPPLEMENTAL INFORMATION (Continued)
|
|
|
|
CUSTOMER LICENSED BEDS UNDER CONTRACT AND PRESCRIPTION DATA
|
|
|
|
The following is a summary of customer licensed beds under
contract and prescription data as of and for the first quarter
ended March 31, 2008 and 2009 (unaudited).
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
|
|
2008
|
|
2009
|
|
Customer licensed beds:
|
|
|
|
|
|
Beginning of period
|
|
|
337,043
|
|
|
|
322,376
|
|
|
Additions
|
|
|
5,157
|
|
|
|
6,762
|
|
|
Losses
|
|
|
(7,974
|
)
|
|
|
(8,393
|
)
|
|
End of period
|
|
|
334,226
|
|
|
|
320,745
|
|
|
|
|
|
|
|
|
Prescription data:
|
|
|
|
|
|
Prescriptions dispensed (in thousands)
|
|
|
10,212
|
|
|
|
9,919
|
|
|
Revenue per prescription dispensed
|
|
$
|
47.02
|
|
|
$
|
45.71
|
|
|
Gross profit per prescription dispensed
|
|
$
|
6.83
|
|
|
$
|
7.03
|
|
Use of Non-GAAP Measures
PharMerica calculates Adjusted EBITDA as provided in the reconciliation
below and calculates Adjusted EBITDA Margin by taking Adjusted EBITDA
and dividing it by revenues. PharMerica calculates and uses Adjusted
EBITDA as an indicator of its ability to generate cash from reported
operating results. The measurement is used in concert with net income
and cash flows from operations, which measure actual cash generated in
the period. In addition, PharMerica believes that Adjusted EBITDA and
Adjusted EBITDA Margin are supplemental measurement tools used by
analysts and investors to help evaluate overall operating performance
and the ability to incur and service debt and make capital expenditures.
Adjusted EBITDA, as defined in the Company’s Credit Agreement, is used
in conjunction with PharMerica’s debt leverage ratio and this
calculation sets the applicable margin for the quarterly interest
charge. Adjusted EBITDA, as defined in the Company’s Credit Agreement,
is not the same calculation as this Adjusted EBITDA table. Adjusted
EBITDA does not represent funds available for PharMerica’s discretionary
use and is not intended to represent or to be used as a substitute for
net income or cash flows from operations data as measured under U.S.
generally accepted accounting principles (“GAAP”). The items excluded
from Adjusted EBITDA but included in the calculation of PharMerica’s
reported net income are significant components of the accompanying
unaudited condensed consolidated income statements, and must be
considered in performing a comprehensive assessment of overall financial
performance. PharMerica’s calculation of Adjusted EBITDA may not be
consistent with calculations of EBITDA used by other companies.
PharMerica calculates and uses diluted earnings per share, exclusive of
integration, merger and acquisition related costs and other charges, as
an indicator of its core operating results. The measurement is used in
concert with net income and diluted earnings per share, which measure
actual earnings per share generated in the period. PharMerica believes
the exclusion of these charges in expressing earnings per share provides
management with a useful measure to assess period to period
comparability and is useful to investors in evaluating PharMerica’s
operating results from period to period. Diluted earnings per share,
exclusive of integration, merger and acquisition related costs and other
charges, does not represent the amount that effectively accrues directly
to stockholders (i.e., such costs are a reduction in earnings and
stockholders’ equity) and is not intended to represent or to be used as
a substitute for diluted earnings per share as measured under GAAP. The
integration, merger and acquisition related costs and other charges
excluded from the diluted earnings per share are significant components
of the accompanying unaudited condensed consolidated income statements,
and must be considered in performing a comprehensive assessment of
overall financial performance.
|
PHARMERICA CORPORATION
|
|
SUPPLEMENTAL INFORMATION (Continued)
|
|
|
|
UNAUDITED RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
|
|
(In millions)
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
|
|
2008
|
|
2009
|
|
Net income
|
|
$
|
3.3
|
|
|
$
|
8.2
|
|
|
Add:
|
|
|
|
|
|
Interest expense, net
|
|
|
3.7
|
|
|
|
3.2
|
|
|
Integration, merger and acquisition related costs and other charges
|
|
|
4.1
|
|
|
|
2.0
|
|
|
Provision for income taxes
|
|
|
2.5
|
|
|
|
5.3
|
|
|
Depreciation and amortization expense
|
|
|
7.5
|
|
|
|
6.5
|
|
|
Adjusted EBITDA
|
|
$
|
21.1
|
|
|
$
|
25.2
|
|
|
Adjusted EBITDA Margin
|
|
|
4.3
|
%
|
|
|
5.4
|
%
|
|
UNAUDITED RECONCILIATION OF DILUTED EARNINGS PER SHARE
|
|
TO ADJUSTED DILUTED EARNINGS PER SHARE
|
|
(In whole numbers)
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
|
|
2008
|
|
2009
|
|
Diluted earnings per common share
|
|
$
|
0.11
|
|
$
|
0.27
|
|
Integration, merger and acquisition related costs and other charges
|
|
|
0.08
|
|
|
0.04
|
|
Adjusted diluted earnings per common share after impact of above item
|
|
$
|
0.19
|
|
$
|
0.31
|
|
UNAUDITED RECONCILIATION OF ADJUSTED EBITDA
|
|
TO NET OPERATING CASH FLOWS
|
|
(In millions)
|
|
|
|
|
|
Three Months Ended
March 31,
|
|
|
|
2008
|
|
2009
|
|
Adjusted EBITDA
|
|
$
|
21.1
|
|
|
$
|
25.2
|
|
|
Interest expense, net
|
|
|
(3.7
|
)
|
|
|
(3.2
|
)
|
|
Provision for income taxes
|
|
|
(2.5
|
)
|
|
|
(5.3
|
)
|
|
Integration, merger and acquisition related costs and other charges
|
|
|
(3.6
|
)
|
|
|
(1.8
|
)
|
|
Provision for bad debt
|
|
|
5.2
|
|
|
|
7.1
|
|
|
Stock-based compensation
|
|
|
1.0
|
|
|
|
0.6
|
|
|
Amortization of deferred financing fees
|
|
|
0.1
|
|
|
|
0.1
|
|
|
Deferred income taxes
|
|
|
2.5
|
|
|
|
4.8
|
|
|
Loss on sales of equipment
|
|
|
–
|
|
|
|
0.1
|
|
|
Other
|
|
|
(0.3
|
)
|
|
|
(0.1
|
)
|
|
Changes in assets and liabilities
|
|
|
(8.6
|
)
|
|
|
(13.6
|
)
|
|
Net Cash Flows from Operating Activities
|
|
$
|
11.2
|
|
|
$
|
13.9
|
|
Source: PharMerica Corporation
PharMerica Corporation
Michael J. Culotta, 502-627-7475
Executive
Vice President and Chief Financial Officer
|
